TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06735755: A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa) Homozygous or Compound Heterozygous for the G6PC1 c.247C>T (p.R83C) Variant

Sponsor: Beam Therapeutics Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 36 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$4,712,740

Rescue Site Savings

+$3,104,200

Unlock Full NCT06735755 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06735755 Rescue Dossier →